Cargando…
Targeted Enzymatic VLP‐Nanoreactors with β‐Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease
Gaucher disease is a genetic disorder and the most common lysosomal disease caused by the deficiency of enzyme β‐glucocerebrosidase (GCase). Although enzyme replacement therapy (ERT) is successfully applied using mannose‐exposed conjugated glucocerebrosidase, the lower stability of the enzyme in blo...
Autores principales: | Chauhan, Kanchan, Olivares‐Medina, Cindy N., Villagrana‐Escareño, Maria V., Juárez‐Moreno, Karla, Cadena‐Nava, Rubén D., Rodríguez‐Hernández, Ana G., Vazquez‐Duhalt, Rafael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804995/ https://www.ncbi.nlm.nih.gov/pubmed/35918294 http://dx.doi.org/10.1002/cmdc.202200384 |
Ejemplares similares
-
Design of a VLP-nanovehicle for CYP450 enzymatic activity delivery
por: Sánchez-Sánchez, Lorena, et al.
Publicado: (2015) -
Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer
por: Chauhan, Kanchan, et al.
Publicado: (2018) -
Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021) -
Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016) -
Analysis of glucocerebrosidase (GBA) gene mutations in Iranian patients with Gaucher disease
por: MOZAFARI, Hadi, et al.
Publicado: (2021)